Product logins

Find logins to all Clarivate products below.


Swarali Tadwalkar

Principal Consultant

Swarali has over 9 years of experience in providing consultancy support for the design and implementation of market sizing, epidemiology and real-world studies. Swarali has led multiple projects across a wide array of therapy areas, including rare diseases, oncology, and metabolic disorders. Swarali acts as a project lead/manager for projects involving data collation, epidemiology analysis, market sizing strategies, data forecasting and deriving insights from various real-world data assets. She supports clients in various aspects, such as developing strategies to understand disease market, meeting preparation and development of evidence dossiers/briefing books for FDA/EMA submissions. Throughout her career, she has developed a strong interest in tackling data challenges for analyzing complex disease indications and deriving robust insights especially for rare diseases.

Swarali has presented epidemiology forecasts and results from real-world data studies at various conferences, including, the World Cancer Congress and the Indian Cancer Congress. She holds an MPH degree from the University of South Florida, Tampa specializing in Epidemiology and Biostatistics and a BE in Biotechnology from the University of Mumbai.

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全